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Ebola: worldwide dissemination risk and response priorities
The scale of the current outbreak of Ebola virus disease 
in west Africa is staggering. Thousands of infections and 
deaths have been reported in recent months, and unless 
major changes occur in the situation, incidence of Ebola 
virus disease has been projected to continue to grow and 
cumulative incidence to exceed 20 000 by November.1 A 
humanitarian crisis that stretches far beyond the impact 
of Ebola virus infections is unfolding in Africa, devastating 
the health systems and economies in aﬀ ected countries.2 
In the present outbreak, most infections remain conﬁ ned 
to west Africa, although four cases have been detected 
outside this region: three cases diagnosed in Dallas, USA 
(of which one infection was contracted in Liberia and two 
were associated with nosocomial transmission from the 
ﬁ rst case), and one case in Madrid, Spain, associated with 
nosocomial transmission (ﬁ gure).
In The Lancet, Isaac Bogoch and colleagues3 report on 
the potential for international dissemination of Ebola 
virus disease. Their assessment of risk for diﬀ erent 
countries is an advance over previous work,4 which 
analysed ﬂ ight networks and connectivity, but did not 
account for passenger ﬂ ows and ﬁ nal destinations. 
Because of the assumptions of uniform risk across 
the population and constant prevalence of infection 
(whereas, in fact, risk within the population is not likely to 
be uniform and incidence is doubling every 15–30 days),1 
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Figure: Geographic location of reported cases of Ebola virus disease as of Oct 16, 2014
Among all reported cases in the 2014 outbreak to date, most infections have been contracted in three countries in west Africa: Guinea, Liberia, and Sierra Leone.
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the relative risks comparing diﬀ erent countries can be 
more valuable than the estimated absolute risks. Bogoch 
and colleagues report that the two countries at highest 
risk of receiving cases are Ghana and Senegal and, outside 
Africa, the risk for export to the UK or France combined 
was estimated to be about eight times higher than the 
risk for export to the USA (15·8 vs 2·0).3 In other words, 
for every case of Ebola virus disease exported to the USA, 
the authors predict that there will be roughly eight cases 
exported to the UK or France combined.
Bogoch and colleagues3 then studied the potential 
for exit and entry screening to reduce export of 
unidentiﬁ ed infections, concluding that exit screening 
would be a much more eﬃ  cient approach than entry 
screening. We would like to add several points to 
this discussion. First, international support would be 
essential for implementation of exit screening in the 
three highly-aﬀ ected resource-poor countries in west 
Africa. However, implementation of more stringent 
checks beyond what is already being done could be very 
challenging. The aﬀ ected countries have many urgent 
priorities—resources including money, personnel, 
medical equipment, and supplies are urgently needed to 
expand capacity for detection, diagnosis, and treatment 
of patients with Ebola virus disease, and to implement 
isolation and contact tracing, which are currently the 
best available interventions to control the outbreak. 
Meanwhile, the outbreak is having a catastrophic eﬀ ect 
on the local health-care systems, which were already 
fragile.2,5 No announcements have been made yet 
about earmarked contributions from the international 
community to support exit screening. 
Second, exit and entry screening might not have 
a substantial eﬀ ect on export rates, because of 
the long incubation period of the disease (average 
8–10 days, range 2–21 days),1 combined with rapid 
disease progression after onset, so that most 
exportations would be incubating infections missed 
at border screening points. Finally, a choice is posed 
between entry and exit screening in Bogoch and 
colleagues’ study,3 with exit screening shown to be more 
eﬃ  cient than entry screening and the combination of 
entry and exit screening shown to have little incremental 
usefulness. However, some countries have implemented 
and will continue entry screening6,7 for various reasons. 
Subject to entry screening already being implemented, 
exit screening from the aﬀ ected countries might not 
have incremental utility, especially considering the other 
urgent priorities in the region. In addition to any entry or 
exit screening, vigilance within countries is essential for 
early detection of imported cases of Ebola virus disease.3
There are several important near-future research needs. 
Perhaps most urgent is a better understanding of the 
eﬀ ectiveness of existing treatment options, including 
convalescent serum. In the medium term, it is hoped that 
new vaccines and drugs will be available quickly for human 
clinical trials and in exposed populations.8 The WHO Ebola 
Response team has neatly summarised the transmission 
dynamics and epidemiological characteristics including the 
reproductive number, incubation period, and case fatality 
risk in the current Ebola virus outbreak,1 but one important 
unknown is the proportion of infections that are 
asymptomatic or mildly symptomatic. If mild infections 
do occur and are infectious, disease control outside 
west Africa might be increasingly challenging. However, 
this scenario is thought to be unlikely.9 One particularly 
pressing need is for the reassessment of appropriate 
procedures for infection control, and the potential for 
the virus to spread via small particle aerosols10 in addition 
to via contact with infected patients or their bodily 
ﬂ uids. Infection of health-care personnel in west Africa is 
often attributed to the scarcity of appropriate protective 
equipment and supplies, or inadequate administrative 
controls.11,12 However, the nosocomial cases in Dallas and 
Madrid have raised the concern that present protocols 
might not be suﬃ  cient to protect health-care personnel 
fully against infection, particularly if cases are managed in 
health-care facilities that are not fully prepared.
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In The Lancet, Ben Slotman and colleagues report the 
results of a phase 3 trial of thoracic radiotherapy for 
small-cell lung cancer.1 The trial is the most recent in a 
long line of studies showing that local radiotherapy 
beneﬁ ts patients with small-cell lung cancer, a 
disease characterised by a bulky intrathoracic mass at 
presentation, a high propensity for metastasis, and high 
chemosensitivity, but with a poor prognosis.2
Combination of diﬀ erent modalities of cancer 
treatment oﬀ ers several advantages. Reduction of 
the bulk of the tumour will increase blood ﬂ ow and 
oxygenation to the tumour. The absence of overlapping 
toxic eﬀ ects enables full eﬀ ective doses of each treatment 
modality to be maintained, important for surmounting 
resistance to any one modality. Pignon and colleagues3 
described a 5% beneﬁ t in survival at 3 years when thoracic 
radiotherapy was added to induction chemotherapy for 
patients with limited stage disease. The beneﬁ t did not 
become apparent until about a year after randomisation.
De Ruysscher and co-workers conﬁ rmed a postulated 
interaction between chest irradiation and chemotherapy 
by showing better long-term survival if the overall 
treatment time for radiotherapy was shorter than 
30 days.4 This approach requires concomitant 
administration of both treatments and accelerated 
fractionation of radiotherapy. Furthermore, combined 
treatment modalities enable the eradication of 
micrometastatic disease in pharmacological sanctuaries—
eg, the brain. A reduction in the incidence of symptomatic 
brain metastases and a 6% beneﬁ t in overall survival at 
3 years were reported with the sequential addition of 
prophylactic cranial irradiation in responding patients 
with stage 1–3 disease.5 The European Organisation for 
Research and Treatment of Cancer reported a doubling 
of 1-year survival with cranial irradiation in responding 
patients with extensive stage disease without a 
deleterious eﬀ ect on overall health status.6
It took several decades and the pooling of data from 
hundreds of patients to obtain these results, but combined 
chemotherapy and prophylactic cranial irradiation are now 
considered the standard of care in many clinical guidelines.7 
The next logical step was to irradiate the tumour bulk 
in patients with clinically evident metastases. Slotman 
and colleagues1 randomly assigned nearly 500 patients 
responding to ﬁ rst-line chemotherapy to either standard 
follow-up or thoracic irradiation consisting of ten fractions 
of 3 Gy. All patients underwent prophylactic cranial 
irradiation and no serious toxic eﬀ ects were reported. 
Similar to early stage disease, the survival curves separated 
only at nine months after randomisation, favouring the 
thoracic radiotherapy group by 18 months. At 2 years, 
overall survival was 13% in the group of patients receiving 
thoracic radiotherapy versus 3% without radiotherapy; the 
number needed to treat for one more patient to survive 
for 2 years was 10·6. Presumably, the competing risk of 
death caused by extrathoracic metastatic disease that is 
refractory to chemotherapy becomes less important than 
the risk caused by uncontrolled disease at the primary 
site in unirradiated patients at 2 years. Hence, there is an 
ongoing need for development of novel drugs targeted 
against molecular alterations in small-cell lung cancer.8
The rationale for Slotman and colleagues’ study was 
sound: intrathoracic progression was common in a 
previous trial of prophylactic cranial irradiation for patients 
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3 Bogoch II, Creatore MI, Cetron M, et al. Assessment of the potential for 
international dissemination of Ebola virus via commercial air travel during the 
2014 west African outbreak. Lancet 2014; published online Oct 21. 
http://dx.doi.org/10.1016/S0140-6736(14)61828-6.
4 Gomes MFC, Piontti AP, Rossi L, et al. Assessing the international spreading 
risk associated with the 2014 west African Ebola outbreak. 
PLoS Currents Outbreaks 2014; published online Sept 2. DOI:10.1371/currents.
outbreaks.cd818f63d40e24aef769dda7df9e0da5.
5 The Lancet. Ebola: a failure of international collective action. Lancet 2014; 
384: 637.
6 Centers for Disease Control and Prevention. Press release: enhanced Ebola 
screening to start at ﬁ ve US airports and new tracking program for all people 
entering US from Ebola-aﬀ ected countries. 2014. http://www.cdc.gov/
media/releases/2014/p1008-ebola-screening.html (accessed Oct 10, 2014).
7 Booth R. UK to introduce Ebola screening as death of Briton reported in 
Macedonia. 2014. http://www.theguardian.com/world/2014/oct/09/uk-
screening-airports-ebola-symptoms (accessed Oct 10, 2014).
8 Kanapathipillai R, Restrepo AM, Fast P, et al. Ebola vaccine—an urgent 
international priority. N Engl J Med 2014; published online Oct 7. DOI:10.1056/
NEJMp1412166.
9 Baxter AG. Symptomless infection with Ebola virus. Lancet 2000; 
355: 2178–79.
10 MacIntyre CR, Chughtai AA, Seale H, Richards GA, Davidson PM. Respiratory 
protection for healthcare workers treating Ebola virus disease (EVD): are 
facemasks suﬃ  cient to meet occupational health and safety obligations? 
Int J Nurs Stud 2014; 51: 1421–26.
11 Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 
377: 849–62.
12 Fowler RA, Fletcher T, Fischer WA, 2nd, et al. Caring for critically ill patients 
with ebola virus disease. Perspectives from west Africa. 
Am J Respir Crit Care Med 2014; 190: 733–37.
Published Online
September 14, 2014
http://dx.doi.org/10.1016/
S0140-6736(14)61252-6
See Articles page 36
Co
rb
is
